文献速递造血干细胞移植与细胞治疗

异基因造血干细胞移植后腺病毒感染26例的诊断与治疗

[Diagnosis and treatment of 26 cases of adenovirus infection after allogeneic hematopoietic stem cell transplantation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2023-01-01

该研究回顾分析2018至2022年苏州大学附属第一医院移植后病房26例异基因造血干细胞移植后腺病毒感染患者,中位年龄30岁,腺病毒感染中位时间为移植后95天,全因死亡率(88.5±7.1)%,归因死亡率45.5%,年龄>30岁是发生腺病毒病的危险因素(P=0.03)。

要点

  • 年龄>30岁是异基因造血干细胞移植后发生腺病毒病的危险因素(P=0.03)。
  • 26例中22例死亡,全因死亡率(88.5±7.1)%,归因死亡率45.5%。
  • 无症状感染者与腺病毒病患者100天生存率差异无统计学意义(37.5%对22.2%,HR=1.83,95%CI 0.66~5.04,P=0.24)。

核心结论

  • 年龄>30岁是发生腺病毒病的危险因素,异基因造血干细胞移植后腺病毒感染患者死亡率较高。

研究设计与样本

  • 收集2018至2022年苏州大学附属第一医院移植后病房收治的26例异基因造血干细胞移植后腺病毒感染患者,分析其基线资料、临床特征、治疗和随访情况。

主要发现

  • 26例患者中位年龄30(22,44)岁,22例接受亲缘单倍体造血干细胞移植,3例接受无关移植,1例接受脐血干细胞移植,25例预处理方案中包含抗胸腺细胞球蛋白(ATG)。
  • 腺病毒感染发生的中位时间为移植后95(44,152)天,中位外周血淋巴细胞计数为0.30(0.11,0.69)×10^9/L,12例合并急性移植物抗宿主病,24例在诊断时仍接受抗排异治疗。
  • 16例除腺病毒感染外合并其他感染,8例为无症状感染,18例为腺病毒病,其中肺炎38.89%、胃肠炎38.89%、脑炎33.33%、肝炎5.56%、泌尿道炎症5.56%。
  • 18例进行免疫抑制剂减撤治疗,所有患者均使用至少一种抗病毒药物,其他治疗包括大剂量丙种球蛋白及供者淋巴细胞输注;10例腺病毒感染好转,16例进展或无效。
  • 中位随访时间30(7,237)天,22例患者死亡,全因死亡率为(88.5±7.1)%,归因死亡率为45.5%。

关键数值与推荐

  • 年龄>30岁是发生腺病毒病的危险因素(P=0.03)。
  • 无症状感染者与腺病毒病患者100天生存率差异无统计学意义(37.5%对22.2%,HR=1.83,95%CI 0.66~5.04,P=0.24)。

临床怎么用

  • 18例进行免疫抑制剂减撤治疗,所有患者均使用至少一种抗病毒药物,其他治疗包括大剂量丙种球蛋白及供者淋巴细胞输注。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the clinical characteristics and prognosis of adenovirus infection after allogeneic hematopoietic stem cell transplantation. Methods: A total of 26 patients with adenovirus infection admitted to the posttransplant ward of the First Affiliated Hospital of Soochow University from 2018 to 2022 were enrolled. Their data on baseline and clinical characteristics, treatment, and follow-up were analyzed. Results: The median patient age was 30 (22, 44) years. Twenty-two patients received related haploid stem cell transplantation, three received unrelated stem cell transplantation, and one received umbilical cord stem cell transplantation. Antithymocyte globulin was included in the conditioning regimen in 25 patients. The median time of adenovirus infection was +95 (+44, +152) days. The median peripheral blood lymphocyte count was 0.30 (0.11, 0.69) × 10(9)/L. Twelve patients had acute graft-versus-host disease. Twenty-four patients received antirejection therapies at diagnosis. Sixteen cases had combined infection with other pathogens with adenovirus infection. Eight cases were diagnosed as asymptomatic infection, and 18 were diagnosed as adenovirus disease, including pneumonia (38.89% ) , gastrointestinal disease (38.89% ) , encephalitis (33.33% ) , hepatitis (5.56% ) , and urinary tract inflammation (5.56% ) . The age of >30 years was a risk factor for adenovirus disease (P=0.03) . Eighteen patients received tapering of immunosuppression, and all 26 patients received at least one antiviral drug. Other treatments included high-dose gamma globulin and donor lymphocyte infusion. Adenovirus infection improved in 10 cases and progressed in 16 cases. The median follow-up time was 30 (7, 237) days. Twenty-two patients died. The all-cause mortality rate was (88.5±7.1) % , and the attributable mortality rate was 45.5% . There was no significant difference in the 100 d survival rate between asymptomatic infected patients and patients diagnosed with adenovirus disease (37.5% vs 22.2% , HR=1.83, 95% CI 0.66-5.04, P=0.24) . Conclusion: The age of >30 years was a risk factor for adenovirus disease. Mortality was high in patients with adenovirus infection after allogeneic hematopoietic stem cell transplantation. 目的: 分析异基因造血干细胞移植后腺病毒感染患者的临床特征及预后。 方法: 收集2018-2022年苏州大学附属第一医院移植后病房收治的26例异基因造血干细胞移植后腺病毒感染患者,分析患者基本资料、临床特征、治疗和随访情况。 结果: 26例患者中位年龄30(22,44)岁。22例(84.62%)接受亲缘单倍体造血干细胞移植,3例(11.54%)接受无关移植,1例(3.85%)接受脐血干细胞移植。25例(96.15%)预处理方案中包含ATG。腺病毒感染发生的中位时间为移植后95(44,152)d。中位外周血淋巴细胞计数为0.30(0.11,0.69)×10(9)/L。12例(46.15%)合并急性移植物抗宿主病。24例(92.31%)在诊断时仍接受抗排异治疗。16例(61.54%)患者除腺病毒感染外,合并其他感染。8例(30.77%)为无症状感染,18例(69.23%)为腺病毒病:肺炎(38.89%)、胃肠炎(38.89%)、脑炎(33.33%)、肝炎(5.56%)、泌尿道炎症(5.56%)。年龄>30岁是发生腺病毒病的危险因素(P=0.03)。18例(69.23%)进行免疫抑制剂减撤治疗,所有患者均使用至少一种抗病毒药物,其他治疗包括大剂量丙种球蛋白及供者淋巴细胞输注。10例(38.46%)腺病毒感染好转,16例(61.54%)进展或无效。中位随访时间为30(7,237)d,22例患者死亡。全因死亡率为(88.5±7.1)%,归因死亡率为45.5%,无症状感染者与腺病毒病患者100 d生存率差异无统计学意义(37.5%对22.2%, HR=1.83, 95% CI 0.66~5.04, P=0.24)。 结论: 年龄>30岁是发生腺病毒病的危险因素,异基因造血干细胞移植后腺病毒感染患者死亡率较高。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhou F, Chen SN, Wu DP, et al. [Diagnosis and treatment of 26 cases of adenovirus infection after allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37356999. doi:10.3760/cma.j.issn.0253-2727.2023.04.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。